新型恶唑烷酮类药物康替唑胺（MRX-I）针对来自美国和欧洲的革兰氏阳性临床分离株的活性和效价
Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.
作者信息
Carvalhaes Cecilia G, Duncan Leonard R, Wang Wen, Sader Helio S
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
MicuRx Pharmaceuticals, Inc., Foster City, California, USA.
出版信息
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01195-20.
Abstract
Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( = 1,211). Contezolid demonstrated potent activity against (MIC, 0.5/1 mg/liter), coagulase-negative (MIC, 0.25/0.5 mg/liter), spp. (MIC, 0.5/1 mg/liter), and streptococci (MIC, 1/1 mg/liter). Moreover, methicillin-resistant and vancomycin-resistant isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.
摘要
康替唑胺是一种正在研发用于治疗皮肤及皮肤结构感染的新型恶唑烷酮类抗菌药物，对1211株革兰氏阳性临床分离株进行了药敏试验。康替唑胺对金黄色葡萄球菌（MIC，0.5/1mg/L）、凝固酶阴性葡萄球菌（MIC，0.25/0.5mg/L）、肠球菌属（MIC，0.5/1mg/L）和链球菌（MIC，1/1mg/L）显示出强效活性。此外，耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌分离株均被康替唑胺在≤1mg/L浓度下抑制。这些结果支持康替唑胺的临床研发。
相似文献
1
Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.新型恶唑烷酮类药物康替唑胺（MRX-I）针对来自美国和欧洲的革兰氏阳性临床分离株的活性和效价
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01195-20.
2
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.对来自美国和欧洲的临床分离株进行奥马环素活性测试的监测：来自 SENTRY 抗菌监测计划的报告，2016 年至 2018 年。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02488-19.
3
Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.新型氨甲基环素KBP-7072及对照物对2019年哨兵监测计划中1057株来自不同地理位置的近期临床分离株的活性
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0139721. doi: 10.1128/AAC.01397-21. Epub 2021 Oct 11.
4
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).美国医院儿科患者皮肤和皮肤结构感染的革兰阳性临床分离株检测达巴万星的活性（2014-2015 年）。
J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.
5
Contezolid: First Approval.康替唑胺：首次批准。
Drugs. 2021 Sep;81(13):1587-1591. doi: 10.1007/s40265-021-01576-0.
6
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).替加环素活性的监测，检测了来自全球（北美、欧洲、拉丁美洲和亚太地区）收集的临床分离株（2016 年）。
Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.
7
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.对来自美国和欧洲的临床分离株进行奥马环素活性检测的监测：来自 SENTRY 抗菌监测计划的 2017 年结果。
J Glob Antimicrob Resist. 2019 Dec;19:56-63. doi: 10.1016/j.jgar.2019.02.017. Epub 2019 Feb 27.
8
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.2016 年至 2018 年美国皮肤和皮肤结构感染细菌的头孢托罗活性。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.02566-19.
9
Contezolid in complicated skin and soft tissue infection.康替唑胺治疗复杂性皮肤及软组织感染。
Drugs Today (Barc). 2022 Jul;58(7):315-326. doi: 10.1358/dot.2022.58.7.3389002.
10
Activity of Contezolid Against Methicillin-Resistant , Vancomycin-Resistant , and Strains With Linezolid Resistance Genes From China.克奈唑胺对中国耐甲氧西林、耐万古霉素及携带利奈唑胺耐药基因菌株的活性
Front Microbiol. 2021 Aug 19;12:729900. doi: 10.3389/fmicb.2021.729900. eCollection 2021.
引用本文的文献
1
Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats.康替唑胺（MRX-I）与利奈唑胺在Sprague-Dawley大鼠中的安全性评价
Drugs R D. 2025 May 13. doi: 10.1007/s40268-025-00504-x.
2
Compassionate use of contezolid in a toddler with severe community-acquired pneumonia induced by staphylococcus aureus: a case report and follow-up.康替唑胺在一名金黄色葡萄球菌引起的重症社区获得性肺炎幼儿中的同情用药：病例报告及随访
Front Pediatr. 2024 Feb 7;12:1321447. doi: 10.3389/fped.2024.1321447. eCollection 2024.
3
Treatment of MRSA Infection: Where are We?耐甲氧西林金黄色葡萄球菌感染的治疗：我们在哪里？
Curr Med Chem. 2024;31(28):4425-4460. doi: 10.2174/0109298673249381231130111352.
4
Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.异基因造血干细胞移植受者罕见结核病成功治疗的报告——一个典型病例及文献复习。
Front Cell Infect Microbiol. 2023 Oct 16;13:1258561. doi: 10.3389/fcimb.2023.1258561. eCollection 2023.
5
activities of contezolid (MRX-I) against drug-sensitive and drug-resistant .康替唑胺（MRX-I）对药敏和耐药菌的活性
Microbiol Spectr. 2023 Sep 21;11(5):e0462722. doi: 10.1128/spectrum.04627-22.
6
Use of Contezolid for the Treatment of Refractory Infective Endocarditis in a Patient with Chronic Renal Failure: Case Report.使用康替唑胺治疗一名慢性肾衰竭患者的难治性感染性心内膜炎：病例报告
Infect Drug Resist. 2023 Jun 13;16:3761-3765. doi: 10.2147/IDR.S413452. eCollection 2023.
7
Severe Community-Acquired Pneumonia Caused by Methicillin-Sensitive : Successfully Treated with Contezolid - A Case Report and Literature Review.甲氧西林敏感菌引起的重症社区获得性肺炎：用康替唑胺成功治疗——一例报告及文献综述
Infect Drug Resist. 2023 May 23;16:3233-3242. doi: 10.2147/IDR.S406799. eCollection 2023.
8
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.康替唑胺，一种新型恶唑烷酮类抗生素，在临床抗菌治疗中可能改善药物相关性血小板减少症。
Front Pharmacol. 2023 Apr 24;14:1157437. doi: 10.3389/fphar.2023.1157437. eCollection 2023.
9
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.唑烷酮类药物的并排分析，以估计针对分枝杆菌感染的治疗窗。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0165522. doi: 10.1128/aac.01655-22. Epub 2023 Mar 15.
10
The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection.新型恶唑烷酮类药物 TBI-223 对三种耐甲氧西林金黄色葡萄球菌感染的临床前小鼠模型有效。
Microbiol Spectr. 2022 Oct 26;10(5):e0245121. doi: 10.1128/spectrum.02451-21. Epub 2022 Sep 15.
本文引用的文献
1
Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM.利用冷冻电镜对恶唑烷酮类抗生素的核心核糖体结合区域进行表征
ACS Pharmacol Transl Sci. 2020 May 13;3(3):425-432. doi: 10.1021/acsptsci.0c00041. eCollection 2020 Jun 12.
2
Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant : advances in phase I and II trials.耐甲氧西林金黄色葡萄球菌引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）的创新疗法：I 期和 II 期试验的进展。
Expert Opin Investig Drugs. 2020 May;29(5):495-506. doi: 10.1080/13543784.2020.1750595. Epub 2020 Apr 19.
3
When antibiotics fail: a clinical and microbiological perspective on antibiotic tolerance and persistence of Staphylococcus aureus.当抗生素失效时：耐抗生素和金黄色葡萄球菌持续存在的临床和微生物学视角。
J Antimicrob Chemother. 2020 May 1;75(5):1071-1086. doi: 10.1093/jac/dkz559.
4
Assessment of Tedizolid Activity and Resistance Mechanisms against a Collection of spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.评估 Tedizolid 对引起侵袭性感染的 spp. 的活性和耐药机制，包括美国和欧洲医疗中心需要优化达托霉素给药策略的分离株，时间为 2016 年至 2018 年。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00175-20.
5
Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).替加环素对2014 - 2015年在欧洲及周边地区引起感染的革兰氏阳性临床分离株的活性。
J Chemother. 2019 Jul;31(4):188-194. doi: 10.1080/1120009X.2019.1609740. Epub 2019 May 13.
6
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.血流感染的微生物学：来自 SENTRY 抗菌监测计划的 20 年趋势。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00355-19. Print 2019 Jul.
7
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016).从住院细菌性肺炎患者分离的细菌的频率和抗菌药物敏感性的地理和时间变异：来自 20 年 SENTRY 抗菌监测计划（1997-2016）的结果。
J Antimicrob Chemother. 2019 Jun 1;74(6):1595-1606. doi: 10.1093/jac/dkz074.
8
ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.ZAAPS 项目 2016 年成果：使用来自 42 个国家的医疗中心的临床分离株对利奈唑胺进行的一项活性和谱分析。
J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.
9
Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century.耐万古霉素肠球菌：21世纪的治疗挑战
Infect Dis Clin North Am. 2016 Jun;30(2):415-439. doi: 10.1016/j.idc.2016.02.006.
10
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.评价替加环素对金黄色葡萄球菌和对万古霉素、达托霉素或利奈唑胺敏感性降低的肠球菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
Zotero 插件